2012
DOI: 10.20882/adicciones.101
|View full text |Cite
|
Sign up to set email alerts
|

Avances en el desarrollo de productos biológicos para el tratamiento de la adicción a las drogas y las sobredosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0
1

Year Published

2014
2014
2021
2021

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(3 citation statements)
references
References 28 publications
0
2
0
1
Order By: Relevance
“…[5] In contrast, the PK strategy does not require a precise molecular level knowledge of the drug•receptor interaction needed in the PD strategy, but only the ability to decrease drug concentration below its effective concentration. [6] For example, enzyme based therapeutics (e.g. human butyrylcholine esterase) are being explored that can hydrolyze cocaine into its inactive metabolites (ecgonine methyl ester and benzoic acid), thereby creating a negative concentration gradient between the brain and blood which results in a reduced concentration of the drug at its receptor in the brain.…”
mentioning
confidence: 99%
“…[5] In contrast, the PK strategy does not require a precise molecular level knowledge of the drug•receptor interaction needed in the PD strategy, but only the ability to decrease drug concentration below its effective concentration. [6] For example, enzyme based therapeutics (e.g. human butyrylcholine esterase) are being explored that can hydrolyze cocaine into its inactive metabolites (ecgonine methyl ester and benzoic acid), thereby creating a negative concentration gradient between the brain and blood which results in a reduced concentration of the drug at its receptor in the brain.…”
mentioning
confidence: 99%
“…Unfortunately, currently there are no medications in Phase III clinical trials for these disorders and we may be years away from having any pharmacological treatment approved. This is an area where more collaboration among industry, academics, and government agencies is urgently needed (Montoya, 2012;Montoya & McCann, 2010;Ronsley et al, 2020).…”
Section: «Anti-drug Vaccines Produce An Immunological Response Characterized By the Production Of Antibodies Against The Specific Drug Ofmentioning
confidence: 99%
“…Las proteínas portadoras más usadas son la albúmina sérica bovina (BSA, del inglés, bovine serum albumen), la KLH (del inglés, Keyhole limpet haemocyanin) y el toxoide tetánico (TT), entre otras. La unión de los anticuerpos específicos a la droga evita que ésta cruce la barrera hematoencefá-lica, lo que detiene los procesos neurofarmacológicos de la droga y rompe el ciclo de recompensa-adicción, como se esquematiza en la Figura 1 (Kinsey, Jackson, & Orson, 2009;Kosten & Owens, 2005;Montoya, 2012;Moreno & Janda, 2009;Shen, Orson, & Kosten, 2011).…”
Section: Introductionunclassified